#### CORNERSTONE STRATEGIC VALUE FUND INC/ NEW

Form N-O November 26, 2008

> UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

> > FORM N-Q

QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY

Investment Company Act file number 811-05150 Cornerstone Strategic Value Fund, Inc. \_\_\_\_\_\_ (Exact name of registrant as specified in charter) 237 Park Avenue, New York, NY (Address of principal executive offices) (Zip code) Kayadti A. Madison Cornerstone Strategic Value Fund, Inc., 237 Park Avenue, New York, NY 10017 (Name and address of agent for service) Registrant's telephone number, including area code: (212) 272-3550 Date of fiscal year end: December 31, 2008 Date of reporting period: September 30, 2008 ITEM 1: SCHEDULE OF INVESTMENTS \_\_\_\_\_\_ CORNERSTONE STRATEGIC VALUE FUND, INC. SCHEDULE OF INVESTMENTS -- SEPTEMBER 30, 2008 (UNAUDITED) \_\_\_\_\_\_ NO. OF SHARES VALUE DESCRIPTION EQUITY SECURITIES - 99.67% CLOSED-END FUNDS - 1.42% Adams Express Company (a) 49,500 \$ 533,610

Dreman/Claymore Dividend & Income Fund General American Investors Company, Inc. ^

Liberty All-Star Equity Fund

Zweig Fund, Inc.

4,300 22,403 3,000 77,610 96,330 434,448 29,000 103,820

103,820

1,171,891

29,000

CONSUMER DISCRETIONARY - 8.57%		
Amazon.com, Inc. *	5,500	400,180
Comcast Corporation, Class A	28,555	560,535
DIRECTV Group, Inc. (The) *	4,000	104,680
Gap, Inc. (The)	12,200	216,916
Home Depot, Inc. (The)	4,000	103,560
Johnson Controls, Inc.	7,500	227,475
Lowe's Companies, Inc.	11,900	281,911
McDonald's Corporation ^	18,600	1,147,620
News Corporation, Class A ^	18,000	215,820
NIKE, Inc., Class B ^	6,100	408,090
Omnicom Group Inc. ^	6,200	239,072
Staples, Inc. ^	10,800	243,000
Starbucks Corporation *	2,800 6,800	41,636 333,540
Target Corporation Time Warner Inc.	23,500	308,085
TJX Companies, Inc. (The)	3,000	91,560
Toyota Motor Corporation ADR	2,500	214,500
Viacom Inc., Class B *	5,450	135,378
Walt Disney Company (The) ^	59,200	1,816,848
wait Dishey Company (The)	33,200	
		7,090,406
CONSUMER STAPLES - 13.02%	10.000	0.60 0.00
Altria Group, Inc.	13,300	263,872
Anheuser-Busch Companies, Inc.	6,200	402,256
Archer-Daniels-Midland Company ^	3,960	86,764
Colorto Polmolius Company	41,000	2,168,080
Conlara Facds Inc	8,900	670,615 212,114
ConAgra Foods, Inc.	10,900	351,074
CVS Caremark Corporation General Mills, Inc.	10,430 2,500	171,800
H.J. Heinz Company	4,000	199,640
Kimberly-Clark Corporation	2,500	162,100
Kraft Foods Inc, Class A	10,932	358,023
Kroger Co. (The)	13,800	379,224
PepsiCo, Inc.	7,100	506,017
Philip Morris International Inc.	7,300	351,130
Procter & Gamble Company (The)	34,797	2,425,003
Sysco Corporation	9,800	302,134
Walgreen Co.	4,800	148,608
Wal-Mart Stores, Inc. ^	27 <b>,</b> 100	1,623,019
		10,781,473
ENERGY - 13.08%		
Baker Hughes Incorporated	10,600	641,724
BJ Services Company	3 <b>,</b> 500	66,955
Chevron Corporation	24,032	1,982,159
ConocoPhillips	10,474	767,221
ENSCO International Incorporated	2,500	144,075
Exxon Mobil Corporation	50,000	3,883,000
Halliburton Company	13,200	427,548
Marathon Oil Corp.	15,000	598,050
Noble Corporation	2,500	109,750
Occidental Petroleum Corporation	10,500	739,725
Schlumberger Limited	11,500	898,035
Transocean Inc.	2,500	274,600
XTO Energy, Inc.	6,250	290,750
- ·	•	•

		10,823,592
FINANCIALS - 15.03%		
AFLAC Incorporated	7,000	411,250
Allstate Corporation (The) ^	6,800	313,616
American Express Company	9,400	333,042
Bank of America Corporation ^	25 <b>,</b> 138	879 <b>,</b> 830
Bank of New York Mellon Corporation ^	8,254	268,915
Capital One Financial Corporation ^	5,000	255,000
Charles Schwab Corporation (The)	22,000	572 <b>,</b> 000
Chubb Corporation (The)	4,100	225,090
Citigroup Inc.	5,800	118,958
Goldman Sachs Group, Inc. (The)	2,800	358,400
Hartford Financial Services Group, Inc. (The)	3,000	122,970
Hudson City Bancorp, Inc. ^	9,000	166,050
JPMorgan Chase & Co.	47,632	2,224,415
Loews Corporation ^	5,000	197,450
Marsh & McLennan Companies, Inc.	10,000	317,600
MetLife, Inc.	15,200	851 <b>,</b> 200
Morgan Stanley	7,000	161,000
PNC Financial Services Group, Inc.	7,600	567 <b>,</b> 720
Prudential Financial, Inc.	4,200	302,400
State Street Corporation	3,500	199,080
SunTrust Banks, Inc.	5,000	224,950
T. Rowe Price Group Inc.	11,000	590,810
Travelers Companies, Inc. (The)	12,476	563,915
U.S. Bancorp	16,901	608,774
Wells Fargo & Company	42,900	1,610,037
		12,444,472
HEALTHCARE - 12.66%	11 000	644.006
Abbott Laboratories	11,200	644,896
Abbott Laboratories Aetna Inc.	6,000	216,660
Abbott Laboratories Aetna Inc. Amgen Inc. *	6,000 9,900	216,660 586,773
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc.	6,000 9,900 5,000	216,660 586,773 328,150
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company	6,000 9,900 5,000 4,400	216,660 586,773 328,150 353,144
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. *	6,000 9,900 5,000 4,400 3,000	216,660 586,773 328,150 353,144 150,870
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^	6,000 9,900 5,000 4,400 3,000 25,500	216,660 586,773 328,150 353,144 150,870 531,675
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^	6,000 9,900 5,000 4,400 3,000 25,500 2,950	216,660 586,773 328,150 353,144 150,870 531,675 145,376
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^ Covidien Limited	6,000 9,900 5,000 4,400 3,000 25,500 2,950 2,599	216,660 586,773 328,150 353,144 150,870 531,675 145,376 139,722
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^ Covidien Limited Eli Lilly and Company ^	6,000 9,900 5,000 4,400 3,000 25,500 2,950 2,599 4,700	216,660 586,773 328,150 353,144 150,870 531,675 145,376 139,722 206,941
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^ Covidien Limited Eli Lilly and Company ^ Gilead Sciences, Inc. *	6,000 9,900 5,000 4,400 3,000 25,500 2,950 2,599 4,700 7,000	216,660 586,773 328,150 353,144 150,870 531,675 145,376 139,722 206,941 319,060
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^ Covidien Limited Eli Lilly and Company ^ Gilead Sciences, Inc. * Johnson & Johnson	6,000 9,900 5,000 4,400 3,000 25,500 2,950 2,599 4,700 7,000 40,900	216,660 586,773 328,150 353,144 150,870 531,675 145,376 139,722 206,941 319,060 2,833,552
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^ Covidien Limited Eli Lilly and Company ^ Gilead Sciences, Inc. * Johnson & Johnson McKesson Corporation ^	6,000 9,900 5,000 4,400 3,000 25,500 2,950 2,599 4,700 7,000 40,900 2,800	216,660 586,773 328,150 353,144 150,870 531,675 145,376 139,722 206,941 319,060 2,833,552 150,668
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^ Covidien Limited Eli Lilly and Company ^ Gilead Sciences, Inc. * Johnson & Johnson McKesson Corporation ^ Medtronic, Inc.	6,000 9,900 5,000 4,400 3,000 25,500 2,950 2,599 4,700 7,000 40,900 2,800 14,500	216,660 586,773 328,150 353,144 150,870 531,675 145,376 139,722 206,941 319,060 2,833,552 150,668 726,450
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^ Covidien Limited Eli Lilly and Company ^ Gilead Sciences, Inc. * Johnson & Johnson McKesson Corporation ^ Medtronic, Inc. Merck & Co. Inc.	6,000 9,900 5,000 4,400 3,000 25,500 2,950 2,599 4,700 7,000 40,900 2,800 14,500 17,500	216,660 586,773 328,150 353,144 150,870 531,675 145,376 139,722 206,941 319,060 2,833,552 150,668 726,450 552,300
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^ Covidien Limited Eli Lilly and Company ^ Gilead Sciences, Inc. * Johnson & Johnson McKesson Corporation ^ Medtronic, Inc. Merck & Co. Inc. Pfizer Inc. ^	6,000 9,900 5,000 4,400 3,000 25,500 2,950 2,599 4,700 7,000 40,900 2,800 14,500 17,500 23,560	216,660 586,773 328,150 353,144 150,870 531,675 145,376 139,722 206,941 319,060 2,833,552 150,668 726,450 552,300 434,446
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^ Covidien Limited Eli Lilly and Company ^ Gilead Sciences, Inc. * Johnson & Johnson McKesson Corporation ^ Medtronic, Inc. Merck & Co. Inc. Pfizer Inc. ^ Schering-Plough Corporation ^	6,000 9,900 5,000 4,400 3,000 25,500 2,950 2,599 4,700 7,000 40,900 2,800 14,500 17,500 23,560 29,000	216,660 586,773 328,150 353,144 150,870 531,675 145,376 139,722 206,941 319,060 2,833,552 150,668 726,450 552,300 434,446 535,630
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^ Covidien Limited Eli Lilly and Company ^ Gilead Sciences, Inc. * Johnson & Johnson McKesson Corporation ^ Medtronic, Inc. Merck & Co. Inc. Pfizer Inc. ^ Schering-Plough Corporation ^ Stryker Corporation ^	6,000 9,900 5,000 4,400 3,000 25,500 2,950 2,599 4,700 7,000 40,900 2,800 14,500 17,500 23,560 29,000 3,500	216,660 586,773 328,150 353,144 150,870 531,675 145,376 139,722 206,941 319,060 2,833,552 150,668 726,450 552,300 434,446 535,630 218,050
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^ Covidien Limited Eli Lilly and Company ^ Gilead Sciences, Inc. * Johnson & Johnson McKesson Corporation ^ Medtronic, Inc. Merck & Co. Inc. Pfizer Inc. ^ Schering-Plough Corporation ^ UnitedHealth Group Incorporated ^	6,000 9,900 5,000 4,400 3,000 25,500 2,950 2,599 4,700 7,000 40,900 2,800 14,500 17,500 23,560 29,000 3,500 19,500	216,660 586,773 328,150 353,144 150,870 531,675 145,376 139,722 206,941 319,060 2,833,552 150,668 726,450 552,300 434,446 535,630 218,050 495,105
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^ Covidien Limited Eli Lilly and Company ^ Gilead Sciences, Inc. * Johnson & Johnson McKesson Corporation ^ Medtronic, Inc. Merck & Co. Inc. Pfizer Inc. ^ Schering-Plough Corporation ^ Stryker Corporation ^	6,000 9,900 5,000 4,400 3,000 25,500 2,950 2,599 4,700 7,000 40,900 2,800 14,500 17,500 23,560 29,000 3,500	216,660 586,773 328,150 353,144 150,870 531,675 145,376 139,722 206,941 319,060 2,833,552 150,668 726,450 552,300 434,446 535,630 218,050 495,105 163,695 746,188
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^ Covidien Limited Eli Lilly and Company ^ Gilead Sciences, Inc. * Johnson & Johnson McKesson Corporation ^ Medtronic, Inc. Merck & Co. Inc. Pfizer Inc. ^ Schering-Plough Corporation ^ UnitedHealth Group Incorporated ^ WellPoint Inc. *	6,000 9,900 5,000 4,400 3,000 25,500 2,950 2,599 4,700 7,000 40,900 2,800 14,500 17,500 23,560 29,000 3,500 19,500 3,500	216,660 586,773 328,150 353,144 150,870 531,675 145,376 139,722 206,941 319,060 2,833,552 150,668 726,450 552,300 434,446 535,630 218,050 495,105 163,695
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^ Covidien Limited Eli Lilly and Company ^ Gilead Sciences, Inc. * Johnson & Johnson McKesson Corporation ^ Medtronic, Inc. Merck & Co. Inc. Pfizer Inc. ^ Schering-Plough Corporation ^ UnitedHealth Group Incorporated ^ WellPoint Inc. *	6,000 9,900 5,000 4,400 3,000 25,500 2,950 2,599 4,700 7,000 40,900 2,800 14,500 17,500 23,560 29,000 3,500 19,500 3,500	216,660 586,773 328,150 353,144 150,870 531,675 145,376 139,722 206,941 319,060 2,833,552 150,668 726,450 552,300 434,446 535,630 218,050 495,105 163,695 746,188
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^ Covidien Limited Eli Lilly and Company ^ Gilead Sciences, Inc. * Johnson & Johnson McKesson Corporation ^ Medtronic, Inc. Merck & Co. Inc. Pfizer Inc. ^ Schering-Plough Corporation ^ Stryker Corporation ^ UnitedHealth Group Incorporated ^ WellPoint Inc. * Wyeth	6,000 9,900 5,000 4,400 3,000 25,500 2,950 2,599 4,700 7,000 40,900 2,800 14,500 17,500 23,560 29,000 3,500 19,500 3,500	216,660 586,773 328,150 353,144 150,870 531,675 145,376 139,722 206,941 319,060 2,833,552 150,668 726,450 552,300 434,446 535,630 218,050 495,105 163,695 746,188
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^ Covidien Limited Eli Lilly and Company ^ Gilead Sciences, Inc. * Johnson & Johnson McKesson Corporation ^ Medtronic, Inc. Merck & Co. Inc. Pfizer Inc. ^ Schering-Plough Corporation ^ UnitedHealth Group Incorporated ^ WellPoint Inc. * Wyeth  INDUSTRIALS - 10.65%	6,000 9,900 5,000 4,400 3,000 25,500 2,950 2,599 4,700 7,000 40,900 2,800 14,500 17,500 23,560 29,000 3,500 19,500 3,500 20,200	216,660 586,773 328,150 353,144 150,870 531,675 145,376 139,722 206,941 319,060 2,833,552 150,668 726,450 552,300 434,446 535,630 218,050 495,105 163,695 746,188
Abbott Laboratories Aetna Inc. Amgen Inc. * Baxter International Inc. Becton, Dickinson and Company Biogen Idec Inc. * Bristol-Myers Squibb Company ^ Cardinal Health, Inc. ^ Covidien Limited Eli Lilly and Company ^ Gilead Sciences, Inc. * Johnson & Johnson McKesson Corporation ^ Medtronic, Inc. Merck & Co. Inc. Pfizer Inc. ^ Schering-Plough Corporation ^ Stryker Corporation ^ UnitedHealth Group Incorporated ^ WellPoint Inc. * Wyeth  INDUSTRIALS - 10.65% 3M Co.	6,000 9,900 5,000 4,400 3,000 25,500 2,950 2,599 4,700 7,000 40,900 2,800 14,500 17,500 23,560 29,000 3,500 19,500 3,500 20,200	216,660 586,773 328,150 353,144 150,870 531,675 145,376 139,722 206,941 319,060 2,833,552 150,668 726,450 552,300 434,446 535,630 218,050 495,105 163,695 746,188

COV Company tion	C F00	254 705
CSX Corporation	6,500	354,705
Danaher Corporation	3,500	242,900
Deere & Company	8,000	396,000
Emerson Electric Co.	16,500	673,035
FedEx Corp.	2,000	158,080
General Dynamics Corporation ^	3,200	235,584
General Electric Company	61,900	1,578,450
Honeywell International Inc.	5 <b>,</b> 000	207,750
Illinois Tool Works Inc.	7,300	324,485
Lockheed Martin Corporation	4,000	438,680
Norfolk Southern Corporation ^	5 <b>,</b> 500	364,155
Northrop Grumman Corporation	2,500	151,350
Precision Castparts Corp.	2,500	196,950
Raytheon Company	11,000	588,610
Union Pacific Corporation ^	4,000	284,640
United Parcel Service, Inc., Class B	4,100	257,849
United Technologies Corporation	7,500	450,450
Waste Management, Inc.	9,300	292,857
	,,,,,,,	
		8,813,141
INFORMATION TECHNOLOGY - 15.32%		
Adobe Systems Incorporated *	4,200	165,774
Agilent Technologies Inc. *	4,000	118,640
Apple, Inc. *	8,500	966,110
Applied Materials, Inc.	17,800	269,314
Automatic Data Processing, Inc.	4,400	188,100
Cisco Systems, Inc. *	47,900	1,080,624
Corning Incorporated	16,500	258,060
Dell Inc. *	4,700	77,456
eBay Inc. *	2,500	55,950
EMC Corporation ^ *	68,648	821,030
Google Inc. ^ *	4,500	1,802,340
Hewlett-Packard Company	19,900	920,176
Intel Corporation	60,500	1,133,165
International Business Machines Corporation ^	12,600	1,473,696
Microsoft Corporation	65,200	1,740,188
Nortel Networks Corporation *	660	1,478
Oracle Corporation *	39 <b>,</b> 772	807,769
QUALCOMM Inc.	13,000	558,610
Texas Instruments Incorporated	6,400	
Yahoo! Inc. ^ *	6 <b>,</b> 300	108,990
	,	
		12,685,070
MATERIALS - 3.14%		
Alcoa Inc.	20,400	460,632
Dow Chemical Company (The)	5,400	171,612
E. I. du Pont de Nemours and Company	13,500	544,050
Freeport-McMoRan Copper & Gold, Inc. ^	5,000	
International Paper Company ^	7,000	
Monsanto Company ^	5 <b>,</b> 660	
Praxair, Inc.	5,500	394,570
		2,598,601
REAL ESTATE INVESTMENT TRUST - 0.47%		
Simon Property Group, Inc. ^	4,000	388,000
ormon froperty Group, inc.	4,000	
TELECOMMUNICATION SERVICES - 2.69%		

AT&T Inc. Verizon Communications Inc.	56,539 20,300	
		2,229,996
UTILITIES - 3.62%  American Electric Power Company, Inc.  Dominion Resources, Inc.  Duke Energy Corporation  Edison International ^  Exelon Corporation ^  FirstEnergy Corp.  FPL Group, Inc. ^  PG&E Corporation  Public Service Enterprise Group Incorporate		275,394 359,100 187,860 334,950 201,200 187,250 229,530
Southern Company (The) ^	11,900	448,511  2,999,571
TOTAL EQUITY SECURITIES (cost - \$73,491,294)		82,505,564
SHORT-TERM INVESTMENTS - 8.79%  MONEY MARKET SECURITY - 0.72%  JPMorgan U.S. Government Money Market Fund	592,086	592 <b>,</b> 086
REPURCHASE AGREEMENTS - 8.07%  Bear, Stearns & Co. Inc. + ++ (Agreements dated 9/30/2008 to be	PRINCIPAL AMOUNT (000's)	
Bear, Stearns & Co. Inc. + ++ (Agreements dated 9/30/2008 to be repurchased at \$4,767,441, 3.50%, 10/1/2008, collateralized by \$4,908,014 in United States Treasury Bonds) Bear, Stearns & Co. Inc. + ++ (Agreements dated 9/30/2008 to be repurchased at \$1,917,068, 7.00%, 10/1/2008,	AMOUNT	4,766,978
Bear, Stearns & Co. Inc. + ++ (Agreements dated 9/30/2008 to be repurchased at \$4,767,441, 3.50%, 10/1/2008, collateralized by \$4,908,014 in United States Treasury Bonds) Bear, Stearns & Co. Inc. + ++ (Agreements dated 9/30/2008 to be	AMOUNT (000's)	4,766,978 1,916,695
Bear, Stearns & Co. Inc. + ++ (Agreements dated 9/30/2008 to be repurchased at \$4,767,441, 3.50%, 10/1/2008, collateralized by \$4,908,014 in United States Treasury Bonds) Bear, Stearns & Co. Inc. + ++ (Agreements dated 9/30/2008 to be repurchased at \$1,917,068, 7.00%, 10/1/2008, collateralized by \$1,973,384 in United States	AMOUNT (000's) 	
Bear, Stearns & Co. Inc. + ++ (Agreements dated 9/30/2008 to be repurchased at \$4,767,441, 3.50%, 10/1/2008, collateralized by \$4,908,014 in United States Treasury Bonds) Bear, Stearns & Co. Inc. + ++ (Agreements dated 9/30/2008 to be repurchased at \$1,917,068, 7.00%, 10/1/2008, collateralized by \$1,973,384 in United States	AMOUNT (000's) 	1,916,695
Bear, Stearns & Co. Inc. + ++ (Agreements dated 9/30/2008 to be repurchased at \$4,767,441, 3.50%, 10/1/2008, collateralized by \$4,908,014 in United States Treasury Bonds) Bear, Stearns & Co. Inc. + ++ (Agreements dated 9/30/2008 to be repurchased at \$1,917,068, 7.00%, 10/1/2008, collateralized by \$1,973,384 in United States Treasury Bonds)  TOTAL SHORT-TERM INVESTMENTS	AMOUNT (000's) 	1,916,695 6,683,673
Bear, Stearns & Co. Inc. + ++ (Agreements dated 9/30/2008 to be repurchased at \$4,767,441, 3.50%, 10/1/2008, collateralized by \$4,908,014 in United States Treasury Bonds) Bear, Stearns & Co. Inc. + ++ (Agreements dated 9/30/2008 to be repurchased at \$1,917,068, 7.00%, 10/1/2008, collateralized by \$1,973,384 in United States Treasury Bonds)  TOTAL SHORT-TERM INVESTMENTS (cost - \$7,275,759)  TOTAL INVESTMENTS - 108.46%	AMOUNT (000's) 	1,916,695 

5

- (a) Affiliated investment. The Fund holds 0.64% (based on net assets) of Adams Express Company. A director of the Fund also serves as a director to such company. During the nine months ended September 30, 2008 there were no purchases or sales of this security.
- Security or a portion thereof is out on loan.
- \* Non-income producing security.
- ADR American Depositary Receipt
- + Stated interest rate, before rebate earned by borrower of securities on loan.
- ++ Represents investment purchased with collateral received for securities on loan.

Federal Income Tax Cost: At September 30, 2008 the identified cost for federal income tax purposes, as well as the gross unrealized appreciation from investments for those securities having an excess of value over cost, gross unrealized depreciation from investments for those securities having an excess of cost over value and the net unrealized appreciation from investments were \$80,767,053, \$14,997,570, \$(5,983,300), and \$9,014,270, respectively.

The Fund adopted Financial Accounting Standards Board Statement of Financial Accounting Standards No. 157, Fair Value Measurements ("FAS 157"), effective January 1, 2008. In accordance with FAS 157, fair value is defined as the price that the Fund would receive upon selling an investment in a timely transaction to an independent buyer in the principal or most advantageous market of the investment. FAS 157 established a three-tier hierarchy to maximize the use of observable market data and minimize the use of unobservable inputs and to establish classification of fair value measurements for disclosure purposes. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk, for example, the risk inherent in a particular valuation technique used to measure fair value including such a pricing model and/or the risk inherent in the inputs to the valuation technique. Inputs may be observable or unobservable. Observable inputs are inputs from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity's own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The three-tier hierarchy of inputs is summarized in the three broad Levels listed below.

- o Level 1 quoted prices in active markets for identical investments
- Level 2 other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.)
- o Level 3 significant unobservable inputs (including the Fund's own assumptions in determining the fair value of investments)

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used as of September 30, 2008 in valuing the Fund's investments carried at value:

VALUATION INPUTS	INVESTMENTS IN SECURITIES	OTHER FINANCIAL INSTRUMENTS*
Level 1 - Quoted Prices	\$ 82,505,564	\$ -
Level 2 - Other Significant Observable Inputs	7,275,759	_
Level 3 - Significant Unobservable Inputs	_	-
TOTAL	\$ 89,781,323	\$ -

\_\_\_\_\_

\* Other financial instruments include futures, forwards and swap contracts.

The Fund did not have any assets or liabilities that were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at September 30, 2008.

Securities valuation policies and other investment related disclosures are hereby incorporated by reference to the Fund's semi-annual report previously filed with the Securities and Exchange Commission on the Form N-CSR on September 8, 2008 with a file number 811-05150.

Other information regarding the Fund is available in the Fund's most recent semi-annual report filed with the Securities and Exchange Commission on Form N-CSR on September 8, 2008, file number 811-05150. This information is also available to registered shareholders by calling (800) 937-5449. For general inquiries, please call (212) 272-3550. This information is also available on the website of the Securities and Exchange Commission - http://www.sec.gov

#### ITEM 2: CONTROLS AND PROCEDURES

- (a) As of a date within 90 days from the filing date of this report, the principal executive officer and principal financial officer concluded that the registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940 (the "Act")), were effective based on their evaluation of the disclosure controls and procedures required by Rule 30a-3(b) under the Act and Rules 13a-15(b) or 15d-15(b) under the Securities and Exchange Act of 1934.
- (b) There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the Act) that occurred during the registrant's last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the registrant's internal control over financial reporting.

#### ITEM 3: EXHIBITS

 The certifications of the registrant as required by Rule 30a-2(a) under the Act are exhibits to this report.

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Cornerstone Strategic Value Fund, Inc.

/s/ Ralph W. Bradshaw

Name: Ralph W. Bradshaw

Title: Principal Executive Officer

Date: November 26, 2008

Pursuant to the requirements of the Securities Exchange Act of 1934 and

the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

### /s/ Ralph W. Bradshaw

\_\_\_\_\_

Name: Ralph W. Bradshaw

Title: Principal Executive Officer

Date: November 26, 2008

### /s/ Kayadti A. Madison

\_\_\_\_\_

Name: Kayadti A. Madison

Title: Principal Financial Officer

Date: November 26, 2008